<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Korean Med Sci</journal-id><journal-id journal-id-type="pmc-domain-id">658</journal-id><journal-id journal-id-type="pmc-domain">jkms</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7870421</article-id><article-id pub-id-type="pmcid-ver">PMC7870421.1</article-id><article-id pub-id-type="pmcaid">7870421</article-id><article-id pub-id-type="pmcaiid">7870421</article-id><article-id pub-id-type="pmid">33559409</article-id><article-id pub-id-type="doi">10.3346/jkms.2021.36.e54</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject><subj-group subj-group-type="subheading"><subject>Infectious Diseases, Microbiology &amp; Parasitology</subject></subj-group></subj-group></article-categories><title-group><article-title>What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2611-3399</contrib-id><name name-style="western"><surname>Yoo</surname><given-names initials="JH">Jin-Hong</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Infectious Diseases, Department of Internal Medicine, Bucheon St. Mary's Hospital, Bucheon, <country>Korea</country>.</aff><aff id="A2"><label>2</label>Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, <country>Korea</country>.</aff><author-notes><corresp>Address for Correspondence: Jin-Hong Yoo, MD, PhD. Division of Infectious Diseases, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 327 Sosa-ro, Wonmi-gu, Bucheon 14647, Republic of Korea. <email>jhyoo@catholic.ac.kr</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="collection"><day>08</day><month>2</month><year>2021</year></pub-date><volume>36</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">374991</issue-id><elocation-id>e54</elocation-id><history><date date-type="received"><day>31</day><month>1</month><year>2021</year></date><date date-type="accepted"><day>01</day><month>2</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>02</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>12</day><month>02</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-09-19 01:25:13.560"><day>19</day><month>09</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 The Korean Academy of Medical Sciences.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Korean Academy of Medical Sciences</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jkms-36-e54.pdf"/><abstract><p>Coronavirus disease 2019 (COVID-19), which started at the end of 2019 and has spread worldwide, has remained unabated in 2021. Since non-pharmaceutical interventions including social distancing are facing limitations in controlling COVID-19, additional absolute means to change the trend are necessary. To this end, coronavirus-specific antiviral drugs and vaccines are urgently needed, but for now, the priority is to promote herd immunity through extensive nationwide vaccination campaign. In addition to the vaccines based on the conventional technology such inactivated or killed virus or protein subunit vaccines, several vaccines on the new technological platforms, for example, nucleic acids-based vaccines delivered by viral carriers, nanoparticles, or plasmids as a medium were introduced in this pandemic. In addition to achieving sufficient herd immunity with vaccination, the development of antiviral treatments that work specifically against COVID-19 will also be necessary to terminate the epidemic completely.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jkms-36-e54-abf001.jpg"/></p></abstract><kwd-group kwd-group-type="author"><kwd>COVID-19</kwd><kwd>Vaccine</kwd><kwd>Herd Immunity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>As of early 2021, everything is in chaos. Coronavirus disease 2019 (COVID-19), which started at the end of 2019 and hit the whole world, including Korea, from January 2020, has not slowed down even after a year. The momentum declined temporarily in the hot summer, but as winter came, resurgence struck the world without fail, as we ominously anticipated.<xref rid="B1" ref-type="bibr">1</xref></p><p>As the pandemic of COVID-19 shows no signs of waning, everyone naturally and eagerly crave a game changer.</p><sec><title>The game changer</title><p>What is a game changer?</p><p>By definition, it refers to something that can change a situation very drastically. So, what are the conditions for becoming a game changer in a COVID-19 pandemic? Above all, it should be something that can directly act on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In doing so, human-to-human transmission must be prevented by blocking the entry of SARS-CoV-2 to host cells or inhibiting replication so that the virus cannot survive. As a result, it has to terminate the pandemic.</p><p>Based on this, I will review the measures taken so far.</p><p>First of all, let's review non-pharmaceutical interventions including social distancing.</p><p>Social distancing alone could not completely terminate the COVID-19 epidemic. Social distancing is a good means to slow down the rate at which the disease spreads, not a complete blockade. The definition implies the sad premise that all of us will someday get COVID-19 anyway if we do not have a specific antiviral agent or vaccine.<xref rid="B2" ref-type="bibr">2</xref></p><p>Next, what about antivirals or monoclonal antibodies as pharmaceutical treatment?</p><p>Regrettably, antivirals highly specific to SARS-CoV-2 have not yet been released. Several repurposed drugs used in other diseases have been tried for treatment, but have not achieved any dramatic results, although remdesivir shows the modest effect in some clinical indications.<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref></p><p>As a passive immunization, monoclonal antibodies targeting spike protein have limited indications for the treatment and still require further validation.<xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref></p><p>Therefore, these are also insufficient to become game changers. Nevertheless, SARS-CoV-2 specific antiviral must be developed someday as a game changer.</p><p>For now, I expect vaccines to be the most likely game changer. History tells the reason. Various infectious diseases that have plagued mankind in the past history have eventually been ended by the herd immunity through vaccines. Vaccines have been game changers.<xref rid="B8" ref-type="bibr">8</xref></p><p>This is an undeniable fact.</p><p>The necessary and sufficient condition for the termination of the COVID-19 pandemic is to achieve herd immunity, too. This could be obtained by vaccination rather than by natural course.</p><p>Although it typically takes 5&#8211;10 years to develop a vaccine, COVID-19 vaccines have been developed at an unprecedentedly rapid speed. This was possible thanks to the announcement of the whole genome sequence of SARS-CoV-2, advanced vaccine platform technology, and strong governmental support such as &#8220;Operation Warp Speed&#8221;.<xref rid="B9" ref-type="bibr">9</xref><xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref><xref rid="B12" ref-type="bibr">12</xref></p><p>As a result, COVID-19 has provided an opportunity for the paradigm shift in vaccine development. The nationwide vaccination campaign has already begun in several countries. Currently, five types of COVID-19 vaccines are expected to be imported and used in Korea (<xref rid="T1" ref-type="table">Table 1</xref>). The problem is that no one knows yet how effective these new vaccines will be, or whether they will be safe or not.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Summary of coronavirus 2019 vaccines to be imported in Korea</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jkms-36-e54-i001.jpg"/><table frame="hsides" rules="rows"><col width="28.31%" span="1"/><col width="39.46%" span="1"/><col width="17.17%" span="1"/><col width="15.06%" span="1"/><thead><tr><th valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(211,212,235)">Platform</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(211,212,235)">Brand name</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(211,212,235)">Efficacy</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(211,212,235)">Storage at</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Adenoviral vector</td><td valign="top" align="left" rowspan="1" colspan="1">AstraZeneca's AZD-1222</td><td valign="top" align="center" rowspan="1" colspan="1">70.4%</td><td valign="top" align="center" rowspan="1" colspan="1">2&#176;C&#8211;8&#176;C</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(224,224,241)">Adenoviral vector</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(224,224,241)">Johnson &amp; Johnson's Ad26.COV2.S</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(224,224,241)">66%</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(224,224,241)">2&#176;C&#8211;8&#176;C</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">mRNA</td><td valign="top" align="left" rowspan="1" colspan="1">Pfizer's BNT162b2</td><td valign="top" align="center" rowspan="1" colspan="1">95%</td><td valign="top" align="center" rowspan="1" colspan="1">&#8722;70&#176;C</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(224,224,241)">mRNA</td><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(224,224,241)">Moderna's mRNA-1273</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(224,224,241)">94.1%</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(224,224,241)">&#8722;20&#176;C</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Protein subunit</td><td valign="top" align="left" rowspan="1" colspan="1">NovaVax's NVX-COV2373</td><td valign="top" align="center" rowspan="1" colspan="1">89%</td><td valign="top" align="center" rowspan="1" colspan="1">2&#176;C&#8211;8&#176;C</td></tr></tbody></table></alternatives></table-wrap><p>At this point, I will check what we do know and do not know for sure about the COVID-19 vaccine and predict the future prospects. And this review is to be more familiar to general physicians rather than to experts in infectious diseases.</p></sec><sec><title>The spike protein is the target</title><p>The main structural proteins that make up SARS-CoV-2 are the spike protein, the small envelope protein, the membrane protein, and the nucleocapsid protein.<xref rid="B13" ref-type="bibr">13</xref> Among these, spike protein was determined as the most suitable target for the COVID-19 vaccine through several experiments.<xref rid="B14" ref-type="bibr">14</xref><xref rid="B15" ref-type="bibr">15</xref><xref rid="B16" ref-type="bibr">16</xref> Spike proteins play an important role in binding to the angiotensin converting enzyme 2 (ACE2) receptor when coronavirus enters host cells as the first step in invasion.<xref rid="B13" ref-type="bibr">13</xref><xref rid="B17" ref-type="bibr">17</xref> Therefore, neutralizing the receptor binding domain (RBD) of the spike protein will fundamentally block the pathogenesis of coronavirus. This is the strategic core of the COVID-19 vaccine.</p></sec><sec><title>Immunization after natural course of infection versus vaccination</title><p>Most antibodies to SARS-CoV-2 begin to appear within 2 weeks after the onset of symptoms.<xref rid="B18" ref-type="bibr">18</xref> However, based on examples of other coronaviruses, there is a concern that these antibodies could not last very long. Immunity to colds by human coronavirus is less than 6 months, and immunity to SARS or Middle East respiratory syndrome (MERS) coronavirus is about a few years.<xref rid="B19" ref-type="bibr">19</xref><xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref><xref rid="B22" ref-type="bibr">22</xref><xref rid="B23" ref-type="bibr">23</xref></p><p>SARS-CoV-2 has a structural limitation that makes it difficult to produce neutralizing antibodies compared to other RNA viruses. Probably for that reason, the antibody formation after the natural course is not easy and seems to be short-lived.<xref rid="B24" ref-type="bibr">24</xref></p><p>In addition, immunity to SARS-CoV-2 is incomplete only by humoral immunity, and adequate cellular immunity also must be sufficiently induced. In particular, through priming and assistance of CD4+ T cells, sufficient antibody response and CD8+ cytotoxic T lymphocyte (CTL) activation are induced to complete proper immunity. And memory B and T cells should be created to provide long-term immunity.<xref rid="B25" ref-type="bibr">25</xref><xref rid="B26" ref-type="bibr">26</xref><xref rid="B27" ref-type="bibr">27</xref></p><p>The immunity to SARS-CoV-2 is difficult to achieve completely with a natural course of immunization. Moreover, during the natural course of infection, significant exhaustion of T cells occurs, resulting in cell mediated immunity not working smoothly and sufficiently.<xref rid="B28" ref-type="bibr">28</xref> Therefore, immunization by vaccination is necessary. That's what vaccines are for.</p></sec></sec><sec sec-type="other1"><title>VACCINE PLATFORMS</title><p>The platforms for currently used COVID-19 vaccines are: nucleic acid-based vaccines, recombinant viral-vectored vaccines, protein subunit vaccines, and inactivated or killed virus vaccines. Vaccines using these platforms have less immunogenicity than live attenuated virus vaccines, so memory responses are not sufficiently exhibited to control infections in future virus challenges. Therefore, most COVID-19 vaccines require booster injection.<xref rid="B8" ref-type="bibr">8</xref> As of January 2021, 68 vaccines are being tested in clinical trials, 2 have been approved, 20 are in phase 3 and 24 are in phase 2 clinical trials.<xref rid="B29" ref-type="bibr">29</xref></p><sec><title>Vaccines using adenoviral vectors</title><p>This vaccine is injected into the human body with DNA encoding the spike protein embedded in a non-replicating adenovirus. When adenovirus as a shuttle enters the host cell and reaches the nucleus, it translates spike proteins and presents them to the host immune cells to induce immunization.<xref rid="B30" ref-type="bibr">30</xref></p><p>There is something that many people misunderstand. The DNA encoding the spike is not inserted into the host chromosome. Therefore, an undesirable event like insertion-induced mutagenesis does never happen.<xref rid="B31" ref-type="bibr">31</xref></p><p>There is another problem that really worries. As everyone knows, adenovirus is one of the most common viruses that cause colds, so most people have immunity against adenovirus. Therefore, it is highly likely that the function of the adenoviral vector is significantly disrupted due to this pre-existing immunity. This raises concern especially when using a recombinant adenovirus 5 (rAd5) and rAd26, which are human adenoviruses.<xref rid="B32" ref-type="bibr">32</xref> In order to overcome this problem, administering a vaccine directly to the respiratory route (e.g., intranasal spray) is being studied. This is because the respiratory mucosa is the area not influenced by pre-existing immunity.<xref rid="B33" ref-type="bibr">33</xref></p><p>As another method to overcome, a non-human adenovirus such as chimpanzee adenovirus (ChAdOx1) can be used as a vector to evade human's pre-existing immunity.<xref rid="B34" ref-type="bibr">34</xref><xref rid="B35" ref-type="bibr">35</xref><xref rid="B36" ref-type="bibr">36</xref> In addition, chimpanzee adenoviral vectors have stronger immunogenicity than human adenoviral vectors (ChAdOx1 &gt; rAd5 &gt; rAd26).<xref rid="B37" ref-type="bibr">37</xref> The vaccine using the ChAdOx1 is the AstraZeneca vaccine (AZD-1222).</p><sec><title>AstraZeneca's AZD-1222</title><p>AZD-1222 is undergoing a Phase 2/3 clinical trial after a successful animal experiment, and a controversial result was reported in interim analysis.<xref rid="B38" ref-type="bibr">38</xref><xref rid="B39" ref-type="bibr">39</xref> The vaccine efficacy in participants who received two standard doses (day 0 &amp; 28) was 62.1%, whereas in the participants who first received a half-dose (due to an unintended mistake) and then received a standard dose the efficacy was 90.0%. However, based solely on these results, it cannot be concluded that half-dose is actually the most effective minimum dose. Perhaps because the number of participants was not enough, it would be more reasonable to interpret it as a statistical error. In any case, this vaccine still has a lot to be tested. Currently, an additional phase 3 clinical trial is being conducted.</p><p>And another opinion was suggested that 95% efficacy can be expected if booster injection is administered 3 months after the first vaccination.<xref rid="B40" ref-type="bibr">40</xref> However, this 'Winning Formula' must be further scientifically verified. AZD-1222 was first authorized in the United Kingdom (UK), although the phase 3 clinical trial has not yet finished, and nationwide vaccination began since December 2020.<xref rid="B41" ref-type="bibr">41</xref></p><p>AZD-1222 has advantages in terms of supply and transportation as it can be stored at 2&#176;C&#8211;8&#176;C for up to 6 months.</p></sec><sec><title>Sputnik vaccine</title><p>It is a vaccine developed by the National Research Center for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya of the Ministry of Health of the Russian Federation. This is a heterologous COVID-19 vaccine using rAd26 and rAd5 as adenoviral vectors. Currently, a non-randomized phase 1/2 study has been officially published.<xref rid="B42" ref-type="bibr">42</xref></p></sec><sec><title>Johnson &amp; Johnson's Ad26.COV2.S</title><p>This is a vaccine that uses rAd26 as an adenoviral vector. Johnson &amp; Johnson emphasized that SARS-CoV-2 can be successfully immunized with a single standard dose.<xref rid="B43" ref-type="bibr">43</xref> The interim results of the current phase 1/2 clinical trial have been published.<xref rid="B44" ref-type="bibr">44</xref> As of January 29, 2021, a phase 3 clinical trial revealed that the vaccine had an average efficacy of 66% (72% in the US, 66% in Latin America, and 57% in South Africa).<xref rid="B45" ref-type="bibr">45</xref></p></sec><sec><title>CanSino' rAd5 vectored COVID-19 vaccine</title><p>It uses rAd5 as a vector and a phase I human trial has been published.<xref rid="B46" ref-type="bibr">46</xref></p></sec><sec><title>Cellid's AdCLD-CoV19</title><p>This is a replication-defective human adenovirus type 5/35 vector based vaccine currently in a phase 1/2 clinical trial in Korea (ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT04666012">NCT04666012</ext-link>).</p></sec></sec><sec><title>Nucleic acid-based mRNA vaccine</title><p>The mRNA vaccine contains spike protein-encoding mRNAs in lipid nanoparticles and delivers them to host cells. Immunization is achieved by translating spike proteins in the cytoplasm of host cells and presenting them on the cell surface. The priming of CD4+ T cells by dendritic cells leads to activation of CD8+ cytotoxic lymphocytes and production of antibody from B cells.<xref rid="B47" ref-type="bibr">47</xref><xref rid="B48" ref-type="bibr">48</xref></p><p>The bottom line is that the mRNA used in the vaccine is not a natural one. If it is a natural mRNA, it will be destroyed before it is delivered to or translated in the host. The solution to this is the use of nucleoside-modified RNA (ModRNA). Among the nucleosides in the mRNA, uridine was converted to pseudouridine and cytosine was changed to methylcytosine and put them into several spots of RNA sequence. As a result, the secondary structure of RNA changes.<xref rid="B49" ref-type="bibr">49</xref> Thus, the host's ribonuclease (RNase) allows them to pass without recognizing and breaking them.<xref rid="B50" ref-type="bibr">50</xref><xref rid="B51" ref-type="bibr">51</xref></p><p>In addition, toll-like receptors (TLR)-7 and -8, which were on sentry duty in the endosome, also allow them without recognizing.<xref rid="B52" ref-type="bibr">52</xref><xref rid="B53" ref-type="bibr">53</xref><xref rid="B54" ref-type="bibr">54</xref> ModRNA can thus safely arrive at the destination and do whatever it wants to do. Since this platform only delivers mRNA to the host cytoplasm, there seems to be no risk of infection or insertion mutagenesis, and it can activate not only CD4+ T cells but also CD8+ CTLs through cross-presentation.<xref rid="B47" ref-type="bibr">47</xref><xref rid="B55" ref-type="bibr">55</xref><xref rid="B56" ref-type="bibr">56</xref> However, it has not yet been verified in terms of long-term efficacy, and it is unknown whether respiratory mucosal delivery will be successful.<xref rid="B47" ref-type="bibr">47</xref><xref rid="B57" ref-type="bibr">57</xref><xref rid="B58" ref-type="bibr">58</xref></p><sec><title>Pfizer-BioNTech's BNT162b2</title><p>The BNT162b2 vaccine is one of two vaccines currently approved for full use. It consists of two vaccination schedules of 21 days apart. It was 95% effective in protecting COVID-19 in a clinical trial conducted in a total 43,548 participants.<xref rid="B59" ref-type="bibr">59</xref></p><p>Storage should be at &#8722;70&#176;C, and it can be refrigerated until 5 days after thawing.</p></sec><sec><title>Moderna's mRNA-1273</title><p>Moderna's mRNA-1273, along with BNT162b2, is now approved for full use. As a result of the phase 3 study conducted with a total of 30,420 volunteers, the vaccine efficacy was 94.1%.<xref rid="B60" ref-type="bibr">60</xref></p><p>Storage should be at &#8722;20&#176;C, and it can be refrigerated until 30 days after thawing.</p></sec><sec><title>CureVac's CVnCoV</title><p>This is another mRNA vaccine being developed following Moderna and Pfizer-BioNTech, and a phase 2b/3 clinical trial is currently planned. Unlike the previous two mRNA vaccines, it uses unmodifed, natural mRNA. It may be considered strange because it is a framework different from the concept of ModRNA described so far, but in fact, not modifying mRNA is not always unfavorable to induction of immunogenicity. As mRNA itself can also induce an immune response with associated toxicity, it can also induce the strong innate immunity including enhanced activity of interferon type 1.<xref rid="B61" ref-type="bibr">61</xref><xref rid="B62" ref-type="bibr">62</xref></p><p>Anyway, I think that this different mRNA platform is worth watching about how the outcome will be.</p></sec></sec><sec><title>Nucleic acid-based DNA plasmid vaccine</title><p>This vaccine delivers plasmids (for example, pGX9501 in case of INO-4800) equipped with a gene encoding a spike protein by intramuscular injection. At this time, in order to allow these plasmids to enter the host cell smoothly, an electrical pulse is applied to create transient pores in the cell membrane (electroporation).<xref rid="B63" ref-type="bibr">63</xref> Once successfully entering the cell, the plasmids begin to multiply, translate spike proteins, and activate the host's immune system. The INO-4800 vaccine from Inovio Pharmaceuticals has reported the results of a phase 1 clinical trial and is currently in phase 2 trials. INO-4800 can be stored for more than 1 year at room temperature.<xref rid="B64" ref-type="bibr">64</xref></p><p>And GLS-5310 (GeneOne Life Science, ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT04673149">NCT04673149</ext-link>) and GX-19N (Genexine, ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT04715997">NCT04715997</ext-link>) started a phase 1 clinical trial in Korea in 2021.</p></sec><sec><title>Inactivated virus</title><p>Inactivated vaccines are based on a conventional technology platform, and SinoVac's CoronaVac and Sinopharm's BBIBP-CorV are now available in China. SinoVac reported that there were no adverse effects in a phase 1/2 trials, and antibodies production was relatively modest.<xref rid="B65" ref-type="bibr">65</xref> A phase 3 trial is conducted in Brazil, Indonesia and Turkey.</p><p>Sinopharm has also completed a phase 1/2 clinical trial and is currently undergoing a phase 3 trials, approved not only in China, but also in the United Arab Emirates and Bahrain, and is in emergency use in Egypt and Jordan. However, since the efficacy of both vaccines is still uncertain, further verification is needed.<xref rid="B66" ref-type="bibr">66</xref><xref rid="B67" ref-type="bibr">67</xref> In addition, the disadvantage of the inactivated virus vaccine itself is that it is a poor inducer of CD8+ CTL, and because it uses alum as an adjuvant, whether or not antibodies can be effectively delivered to the respiratory mucosa is also a subject to be verified in the future.<xref rid="B68" ref-type="bibr">68</xref></p></sec><sec><title>Protein subunit vaccine</title><p>This is a vaccine of recombinant spike proteins with nanoparticles. This leads to stronger antibody responses than adenoviral vectors or nucleic acid-based vaccines.<xref rid="B69" ref-type="bibr">69</xref> However, the protein itself used in the subunit vaccine is inherently poorly immunogenic, so it needs a good adjuvant. If a conventional adjuvant such as alum is used, the cell-mediated immune response is skewed into Th2 responses. In order to solve these shortcomings, NovaVax's NVX-CoV2373 vaccine cooperated with Sanofi and GlaxoSmithKline to use AS03 and Matrix-M adjuvants to enhance immunogenicity, respectively, and skew cellular immunity to Th1 response.<xref rid="B68" ref-type="bibr">68</xref><xref rid="B70" ref-type="bibr">70</xref> As of January 28, 2021, a phase 3 clinical trial revealed that the vaccine had an average efficacy of 89%.<xref rid="B71" ref-type="bibr">71</xref></p><p>Other protein subunit vaccines are under clinical trials. SK Bioscience launched a phase 1 clinical trial (ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT02905565">NCT02905565</ext-link>) for the NBP2001 vaccine, and COVAXX's multitope peptide-based UB-612 vaccine is in a phase 1 trial (ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT04545749">NCT04545749</ext-link>) in Taiwan. And a phase 2/3 trial (ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT04683224">NCT04683224</ext-link>) is scheduled to begin in Brazil.</p></sec></sec><sec sec-type="other2"><title>CONCERN &#8211; ADVERSE EVENTS</title><p>The COVID-19 vaccines developed to date may be our saviors, but it is true that they also cause us a lot of anxiety. This is because they have been developed at &#8216;warp speed&#8217;, i.e., too quickly, without enough time to verify. The first thing we feel anxious about is the fear of possible adverse events.</p><sec><title>Early adverse events</title><p>Early adverse events are those that occur within 24&#8211;48 hours of vaccination. Pain, fever, or fatigue, etc., which can appear immediately after vaccination, can in fact occur with any other vaccine and are mostly transient.<xref rid="B72" ref-type="bibr">72</xref></p><p>What we should really worry about are severe adverse events.</p><sec><title>Severe allergy</title><p>The most common early severe adverse event is allergy.<xref rid="B73" ref-type="bibr">73</xref> Several episodes of severe allergy after receiving Pfizer-BioNTech or Moderna coronavirus vaccine occurred in the United States, although there have been no fatal cases.<xref rid="B74" ref-type="bibr">74</xref> In order to estimate the causative agent that may induce an allergic response or anaphylaxis, it is necessary to review the ingredients of the vaccine. The ingredients of the mRNA vaccine currently used are largely composed of mRNA, lipid bubbles, and saline salt solution (Tris-buffer).<xref rid="B75" ref-type="bibr">75</xref><xref rid="B76" ref-type="bibr">76</xref><xref rid="B77" ref-type="bibr">77</xref> Excluding Tris-buffer and mRNA, the potent culprit of allergen is likely to be in the lipid bubble. In particular, polyethylene glycol (PEG) and PEG derivatives such as polysorbates are the most potent allergens.<xref rid="B78" ref-type="bibr">78</xref><xref rid="B79" ref-type="bibr">79</xref><xref rid="B80" ref-type="bibr">80</xref></p><p>Therefore, people with a history of allergy to PEG are contraindicated due to a high risk of anaphylaxis after vaccination.<xref rid="B81" ref-type="bibr">81</xref></p></sec><sec><title>Others reported so far</title><p>In the early days of the nationwide vaccination campaign, 2 cases of transverse myelitis occurred, causing a lot of concern, but it turned out to be a patient with multiple sclerosis, and the other one could not reveal a direct causal relationship with the vaccine.<xref rid="B82" ref-type="bibr">82</xref> Four cases of facial palsy occurred, but no evidence was established that it was caused by the vaccine.<xref rid="B83" ref-type="bibr">83</xref> Cases of inflammation of cosmetic facial fillers have also been reported, but it can also happen with other types of vaccines.<xref rid="B84" ref-type="bibr">84</xref> Fainting and syncope often happen. Mostly it is due to vasovagal syncope rather than the vaccine itself.<xref rid="B85" ref-type="bibr">85</xref></p><p>More than anything else, it is death after vaccination that attracts attention. Of course, it is not clear whether there is a causal relationship, so the vaccine alone cannot be blamed. Still, this is an adverse event that should be investigated.<xref rid="B86" ref-type="bibr">86</xref></p></sec></sec><sec><title>Antibody dependent enhancement (ADE)</title><p>It is a paradoxical complication that may occur relatively late among adverse events after vaccination, which can cause infection when vaccination-induced antibodies encounter the next challenge of the virus.<xref rid="B87" ref-type="bibr">87</xref> An example of a typical ADE can be seen in the dengue virus vaccine.<xref rid="B88" ref-type="bibr">88</xref> However, the mechanism of ADE of coronavirus is different from that of dengue virus. It is more similar to the ADE mechanism of the respiratory syncytial virus (RSV) or measles vaccine than that of the Dengue virus vaccine. Dengue virus vaccine enhances Fc receptor-mediated viral entry while being monocyte/macrophage-tropic. However, measles or RSV vaccine (and probably COVID-19 vaccine, too) is non-macrophage-tropic, so viral entry via Fc receptor-mediated endocytosis does not occur, and non-neutralizing antibodies within respiratory tissues form immune complexes with viral antigens, which induces a pro-inflammatory response, activation of complement cascade, and local immune activation, resulting in severe lung injury.<xref rid="B89" ref-type="bibr">89</xref> It is not known which mechanism will work in the COVID-19 vaccine, but one thing in common is that it is driven by non-neutralizing or sub-neutralizing antibodies.<xref rid="B90" ref-type="bibr">90</xref> Therefore, it can be expected that the probability of occurrence of ADE will decrease in inverse relationship to the proportion of neutralizing antibody induced by the vaccine.</p><p>In short, the ability to avoid ADE side effects will depend on how much the currently used COVID-19 vaccines can produce the pure neutralizing antibody.<xref rid="B69" ref-type="bibr">69</xref><xref rid="B91" ref-type="bibr">91</xref></p><p>In this regard, I think nucleic acid-based vaccines might have an advantage over vaccines of other platforms.</p><p>By the way, will ADE really happen someday? We don't know it yet. Even if ADE really does happen, no one knows yet how severe it will be or not. At least a year should pass before we will know when the re-challenge of COVID-19 begins.</p></sec></sec><sec sec-type="other3"><title>CONCERN - WILL THE VACCINE REALLY END THE PANDEMIC?</title><p>This concern will be a key topic that everyone is most curious about in this nationwide vaccination campaign. The primary goal to be achieved is the establishment of sufficient herd immunity. If we achieve the desired level of herd immunity as planned, we can at least end the pandemic. However, it will not completely eradicate COVID-19 from this world. To be honest, everyone is vaguely aware of this fact. Therefore, in any case, we can only discuss returning to normal life once we end this pandemic. In fact, no matter how long this pandemic takes, it will end in the long run. This is because someday herd immunity will be established, whether by vaccines or by the natural course. The bottom line is how quickly and effectively sufficient herd immunity is achieved.</p><p>The variables that can determine efficient herd immunity formation are efficacy of the vaccines, longevity of the immunity (i.e., neutralization antibody and memory cells), and possible emergence of mutant variants.</p><sec><title>Efficacy of the vaccines</title><p>This is the most important, but still unknown area. If we set the basic production rate (R<sub>0</sub>) of COVID-19 at 5.7, the level of herd immunity we have to achieve should be around 80%.<xref rid="B92" ref-type="bibr">92</xref></p><p>The efficacy of vaccines currently approved or in phase 3 clinical trials is approximately 60%&#8211;95%.<xref rid="B39" ref-type="bibr">39</xref><xref rid="B45" ref-type="bibr">45</xref><xref rid="B59" ref-type="bibr">59</xref><xref rid="B60" ref-type="bibr">60</xref><xref rid="B71" ref-type="bibr">71</xref> This is quite a bit higher than expected, even considering these vaccines were developed in an unprecedented rush. It is not impossible to achieve a herd immunity of 80% if this efficacy is working properly even in actual vaccination. To this end, how well the supply is delivered and how quickly the nationwide vaccination campaign is completed will also be important. However, if the actual efficacy in the real world is lower than that in previous clinical trials, it becomes impossible to achieve the expected herd immunity. This is the scenario we are most afraid of right now.</p></sec><sec><title>Longevity of immunity</title><p>Let's talk straightforward. We cannot obtain life-long immunity to SARS-CoV-2 with the currently used vaccines because the vaccines we receive right now are not live attenuated vaccines.</p><p>Therefore, we cannot hope for permanent immunity, and we have to focus on how long we can maintain acquired immunity. The problem is that no one knows how long the immunity to SARS-CoV-2 after booster injection will last.</p><p>The immunity to SARS-CoV-2 does not seem to be shorter than what we were worried about. The latest hopefully optimistic reports continue to be delivered to us. Regardless of the natural course or post vaccination, the durability of the antibody and memory cells against SARS-CoV-2 is estimated to be maintained for at least 4&#8211;8 months, giving hope that it could even last longer than we worried about.<xref rid="B93" ref-type="bibr">93</xref><xref rid="B94" ref-type="bibr">94</xref><xref rid="B95" ref-type="bibr">95</xref><xref rid="B96" ref-type="bibr">96</xref> The immunity to SARS-CoV-2 obtained by vaccination, although not lifelong, is likely to be up to a level capable of suppressing pandemic to some extent.</p></sec><sec><title>Variants</title><p>Currently, variants of SARS-CoV-2 are emerging as an important key in determining whether COVID-19 vaccines can establish sufficient herd immunity. Even now, new variants continue to appear, and those that are currently drawing attention are British B.1.1.7 variant of concern 202012/01 (VOC-202012/01), B.1.351 or 501Y.V2 variant from South Africa, and Columbus Ohio variant.<xref rid="B97" ref-type="bibr">97</xref><xref rid="B98" ref-type="bibr">98</xref><xref rid="B99" ref-type="bibr">99</xref><xref rid="B100" ref-type="bibr">100</xref><xref rid="B101" ref-type="bibr">101</xref><xref rid="B102" ref-type="bibr">102</xref></p><p>Variants discovered so far have a higher rate of transmission than non-variants, but they do not have stronger virulence. Despite this, the reason these variants are a possible trouble is that they can escape neutralizing antibodies due to mutations in the spike protein, thereby impairing the effectiveness of the vaccine.<xref rid="B103" ref-type="bibr">103</xref> Fortunately, these variants have not yet had a significant harm on the COVID-19 vaccine.<xref rid="B104" ref-type="bibr">104</xref> In fact, the optimistic outlook that SARS-CoV-2 vaccines match all currently circulating variants prevailed.<xref rid="B105" ref-type="bibr">105</xref></p><p>However, the possibilities that variants may reduce the effectiveness of the vaccine are being raised steadily.<xref rid="B106" ref-type="bibr">106</xref></p><p>Eventually, there will be a variant that could fully resist vaccines or antibodies someday. This is also the case with the example of seasonal coronaviruses (OC43, 229E, NL63 and HKU1).<xref rid="B107" ref-type="bibr">107</xref></p><p>Given the periodic antigenic drift of these coronaviruses, it is not overly concerned that SARS-CoV-2 could behave the same.</p><p>Moreover, South African mutants in particular reinforce such anxiety.<xref rid="B45" ref-type="bibr">45</xref><xref rid="B71" ref-type="bibr">71</xref><xref rid="B108" ref-type="bibr">108</xref><xref rid="B109" ref-type="bibr">109</xref></p><p>According to a report, the Moderna vaccine was not affected by the British variant, whereas the neutralization effect was reduced against the South African variant.<xref rid="B110" ref-type="bibr">110</xref></p><p>Even if vaccination succeeds in terminating the pandemic effectively, there may be a paradoxical situation in which resistant variants to the vaccine are selected and survived, resulting in more predominant strains. Of course, as we currently have a platform for new technologies such as nucleic acid-based or adenoviral vector vaccines, we will be able to quickly develop more vaccines tailored to the emerging variants. But when this happens, we have to go through the current pandemic situation for a longer period of time than we desired.</p></sec></sec><sec sec-type="other4"><title>CONCLUDING REMARK - THE AGE OF UNCERTAINTY</title><p>According to the Korean government's plan, the nationwide vaccination campaign will begin on February 2021 when this review article is published, and I am obligated to get a vaccine because I am an infectious disease expert and an elderly person. Frankly speaking, I feel a little bit uneasy.</p><p>I am very anxious about the possibility of the vaccine's success and the future of the COVID-19 pandemic.</p><p>Vaccines have been released too quickly that no one knows at this point whether they will work. Even so, I will receive vaccination. Although I can't say that vaccination is the best solution, it would be better to try anything than to do nothing, and based on what is known so far, I think that vaccination could contribute to some extent in alleviating the pandemic.</p><p>Now our government and the media are singing a promising future for vaccination. Of course, reassuring the agitated people comes from good intentions, so there is no need to blame it, but what if we fail to achieve herd immunity? A tragic ending, is that all?</p><p>Considering these bad scenarios, the game changer that can finish the pandemic is perfectly established by inventing antivirals that specifically act on SARS-CoV-2. In the search for antiviral drugs, only repurposed drugs have been verified and tried. But now is the time when SARS-CoV-2 specific antivirals are urgently needed. Currently, several potential therapeutic drugs are being investigated.<xref rid="B111" ref-type="bibr">111</xref><xref rid="B112" ref-type="bibr">112</xref><xref rid="B113" ref-type="bibr">113</xref><xref rid="B114" ref-type="bibr">114</xref><xref rid="B115" ref-type="bibr">115</xref><xref rid="B116" ref-type="bibr">116</xref></p><p>Perhaps, in order to kill SARS-CoV-2, it should be an attachment inhibitor to host cell or a drug that can inhibit replication. I could be wrong but I dare to predict that SARS-CoV-2 specific antivirals will be specific inhibitors of RNA-dependent RNA polymerase.<xref rid="B117" ref-type="bibr">117</xref><xref rid="B118" ref-type="bibr">118</xref></p><p>In conclusion, we will be able to end this tedious and annoying war only if we meet the final puzzle by supplementing the development of specific antivirals as well as vaccines.</p><p>Eventually, we will have to live with the virus.</p><p>However, even then, we will be able to recover to a level close to our pre-pandemic life.</p><p>We still have to wait for the day of victory, although not a perfect triumph.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure:</bold> The author has no potential conflicts of interest to disclose.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>JH</given-names></name></person-group><article-title>Will the third wave of coronavirus disease 2019 really come in Korea?</article-title><source>J Korean Med Sci</source><year>2020</year><volume>35</volume><issue>10</issue><elocation-id>e110</elocation-id><pub-id pub-id-type="pmid">32174068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3346/jkms.2020.35.e110</pub-id><pub-id pub-id-type="pmcid">PMC7073318</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>JH</given-names></name></person-group><article-title>Social distancing and lessons from Sweden's lenient strategy against corona virus disease 2019</article-title><source>J Korean Med Sci</source><year>2020</year><volume>35</volume><issue>27</issue><elocation-id>e250</elocation-id><pub-id pub-id-type="pmid">32657089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3346/jkms.2020.35.e250</pub-id><pub-id pub-id-type="pmcid">PMC7358066</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scavone</surname><given-names>C</given-names></name><name name-style="western"><surname>Brusco</surname><given-names>S</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>M</given-names></name><name name-style="western"><surname>Sportiello</surname><given-names>L</given-names></name><name name-style="western"><surname>Rafaniello</surname><given-names>C</given-names></name><name name-style="western"><surname>Zoccoli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Current pharmacological treatments for COVID-19: what's next?</article-title><source>Br J Pharmacol</source><year>2020</year><volume>177</volume><issue>21</issue><fpage>4813</fpage><lpage>4824</lpage><pub-id pub-id-type="pmid">32329520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bph.15072</pub-id><pub-id pub-id-type="pmcid">PMC7264618</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izda</surname><given-names>V</given-names></name><name name-style="western"><surname>Jeffries</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sawalha</surname><given-names>AH</given-names></name></person-group><article-title>COVID-19: a review of therapeutic strategies and vaccine candidates</article-title><source>Clin Immunol</source><year>2021</year><volume>222</volume><elocation-id>108634</elocation-id><pub-id pub-id-type="pmid">33217545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2020.108634</pub-id><pub-id pub-id-type="pmcid">PMC7670907</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>JH</given-names></name><name name-style="western"><surname>Tomashek</surname><given-names>KM</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>LE</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>AK</given-names></name><name name-style="western"><surname>Zingman</surname><given-names>BS</given-names></name><name name-style="western"><surname>Kalil</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Remdesivir for the treatment of Covid-19 - final report</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>19</issue><fpage>1813</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">32445440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2007764</pub-id><pub-id pub-id-type="pmcid">PMC7262788</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="webpage"><collab>U.S. Food and Drug Administration (FDA)</collab><source>Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19</ext-link></comment></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="webpage"><collab>Korea Biomedical Review</collab><source>Celltrion confirms efficacy of COVID-19 treatment</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.koreabiomed.com/news/articleView.html?idxno=10149">http://www.koreabiomed.com/news/articleView.html?idxno=10149</ext-link></comment></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bijker</surname><given-names>EM</given-names></name></person-group><article-title>A guide to vaccinology: from basic principles to new developments</article-title><source>Nat Rev Immunol</source><year>2020</year><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">33353987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-00479-7</pub-id><pub-id pub-id-type="pmcid">PMC7754704</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>ZG</given-names></name><etal/></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><year>2020</year><volume>579</volume><issue>7798</issue><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32015508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmcid">PMC7094943</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="webpage"><source>Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. NCBI reference sequence: NC_045512.2</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NC_045512">https://www.ncbi.nlm.nih.gov/nuccore/NC_045512</ext-link></comment></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R</given-names></name><name name-style="western"><surname>Halton</surname><given-names>J</given-names></name></person-group><article-title>Developing Covid-19 vaccines at pandemic speed</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>21</issue><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="pmid">32227757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp2005630</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slaoui</surname><given-names>M</given-names></name><name name-style="western"><surname>Hepburn</surname><given-names>M</given-names></name></person-group><article-title>Developing safe and effective Covid vaccines - operation warp speed's strategy and approach</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>18</issue><fpage>1701</fpage><lpage>1703</lpage><pub-id pub-id-type="pmid">32846056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp2027405</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhama</surname><given-names>K</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>R</given-names></name><name name-style="western"><surname>Sircar</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>S</given-names></name><name name-style="western"><surname>Malik</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Coronavirus disease 2019-COVID-19</article-title><source>Clin Microbiol Rev</source><year>2020</year><volume>33</volume><issue>4</issue><elocation-id>e00028-20</elocation-id><pub-id pub-id-type="pmid">32580969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00028-20</pub-id><pub-id pub-id-type="pmcid">PMC7405836</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvatori</surname><given-names>G</given-names></name><name name-style="western"><surname>Luberto</surname><given-names>L</given-names></name><name name-style="western"><surname>Maffei</surname><given-names>M</given-names></name><name name-style="western"><surname>Aurisicchio</surname><given-names>L</given-names></name><name name-style="western"><surname>Roscilli</surname><given-names>G</given-names></name><name name-style="western"><surname>Palombo</surname><given-names>F</given-names></name><etal/></person-group><article-title>SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines</article-title><source>J Transl Med</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>222</fpage><pub-id pub-id-type="pmid">32493510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-020-02392-y</pub-id><pub-id pub-id-type="pmcid">PMC7268185</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchholz</surname><given-names>UJ</given-names></name><name name-style="western"><surname>Bukreyev</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>BR</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name><etal/></person-group><article-title>Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><issue>26</issue><fpage>9804</fpage><lpage>9809</lpage><pub-id pub-id-type="pmid">15210961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0403492101</pub-id><pub-id pub-id-type="pmcid">PMC470755</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Traggiai</surname><given-names>E</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name><name name-style="western"><surname>Kolesnikova</surname><given-names>L</given-names></name><name name-style="western"><surname>Uematsu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gismondo</surname><given-names>MR</given-names></name><etal/></person-group><article-title>An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><issue>8</issue><fpage>871</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">15247913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1080</pub-id><pub-id pub-id-type="pmcid">PMC7095806</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Pu</surname><given-names>J</given-names></name><name name-style="western"><surname>Voronin</surname><given-names>D</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine</article-title><source>Cell Mol Immunol</source><year>2020</year><volume>17</volume><issue>6</issue><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">32203189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-020-0400-4</pub-id><pub-id pub-id-type="pmcid">PMC7091888</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019</article-title><source>Clin Infect Dis</source><year>2020</year><volume>71</volume><issue>16</issue><fpage>2027</fpage><lpage>2034</lpage><pub-id pub-id-type="pmid">32221519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa344</pub-id><pub-id pub-id-type="pmcid">PMC7184337</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callow</surname><given-names>KA</given-names></name><name name-style="western"><surname>Parry</surname><given-names>HF</given-names></name><name name-style="western"><surname>Sergeant</surname><given-names>M</given-names></name><name name-style="western"><surname>Tyrrell</surname><given-names>DA</given-names></name></person-group><article-title>The time course of the immune response to experimental coronavirus infection of man</article-title><source>Epidemiol Infect</source><year>1990</year><volume>105</volume><issue>2</issue><fpage>435</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">2170159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/s0950268800048019</pub-id><pub-id pub-id-type="pmcid">PMC2271881</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>WC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>PH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Richardus</surname><given-names>JH</given-names></name></person-group><article-title>Disappearance of antibodies to SARS-associated coronavirus after recovery</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><issue>11</issue><fpage>1162</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">17855683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc070348</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>LP</given-names></name><name name-style="western"><surname>Wang</surname><given-names>NC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YH</given-names></name><name name-style="western"><surname>Tian</surname><given-names>XY</given-names></name><name name-style="western"><surname>Na</surname><given-names>DY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Duration of antibody responses after severe acute respiratory syndrome</article-title><source>Emerg Infect Dis</source><year>2007</year><volume>13</volume><issue>10</issue><fpage>1562</fpage><lpage>1564</lpage><pub-id pub-id-type="pmid">18258008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1310.070576</pub-id><pub-id pub-id-type="pmcid">PMC2851497</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>JY</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JO</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>JY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Seong</surname><given-names>H</given-names></name><etal/></person-group><article-title>Absence of neutralizing activity in serum 1 year after successful treatment with antivirals and recovery from MERS in South Korea</article-title><source>Clin Exp Vaccine Res</source><year>2019</year><volume>8</volume><issue>1</issue><fpage>86</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">30775355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7774/cevr.2019.8.1.86</pub-id><pub-id pub-id-type="pmcid">PMC6369131</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sariol</surname><given-names>A</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Lessons for COVID-19 immunity from other coronavirus infections</article-title><source>Immunity</source><year>2020</year><volume>53</volume><issue>2</issue><fpage>248</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">32717182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.07.005</pub-id><pub-id pub-id-type="pmcid">PMC7359787</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></name><name name-style="western"><surname>Mohsen</surname><given-names>MO</given-names></name><name name-style="western"><surname>Zha</surname><given-names>L</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>M</given-names></name><name name-style="western"><surname>Speiser</surname><given-names>DE</given-names></name></person-group><article-title>SARS-CoV-2 structural features may explain limited neutralizing-antibody responses</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>2</fpage><pub-id pub-id-type="pmid">33398006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-00264-6</pub-id><pub-id pub-id-type="pmcid">PMC7782831</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciabattini</surname><given-names>A</given-names></name><name name-style="western"><surname>Pettini</surname><given-names>E</given-names></name><name name-style="western"><surname>Medaglini</surname><given-names>D</given-names></name></person-group><article-title>CD4(+) T cell priming as biomarker to study immune response to preventive vaccines</article-title><source>Front Immunol</source><year>2013</year><volume>4</volume><fpage>421</fpage><pub-id pub-id-type="pmid">24363656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2013.00421</pub-id><pub-id pub-id-type="pmcid">PMC3850413</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>J</given-names></name><name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Moderbacher</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>7</issue><fpage>1489</fpage><lpage>1501.e15</lpage><pub-id pub-id-type="pmid">32473127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmcid">PMC7237901</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Kolls</surname><given-names>JK</given-names></name></person-group><article-title>T cell-mediated host immune defenses in the lung</article-title><source>Annu Rev Immunol</source><year>2013</year><volume>31</volume><issue>1</issue><fpage>605</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">23516986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-immunol-032712-100019</pub-id><pub-id pub-id-type="pmcid">PMC3912562</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diao</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ning</surname><given-names>L</given-names></name><etal/></person-group><article-title>Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>827</fpage><pub-id pub-id-type="pmid">32425950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00827</pub-id><pub-id pub-id-type="pmcid">PMC7205903</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="webpage"><collab>The New York Times</collab><source>Coronavirus vaccine tracker</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html">https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html</ext-link></comment></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>S</given-names></name><name name-style="western"><surname>Faheem</surname><given-names>M</given-names></name><name name-style="western"><surname>Hassain</surname><given-names>NA</given-names></name><name name-style="western"><surname>Benslimane</surname><given-names>FM</given-names></name><name name-style="western"><surname>Al Thani</surname><given-names>AA</given-names></name><name name-style="western"><surname>Zaraket</surname><given-names>H</given-names></name><etal/></person-group><article-title>Platforms exploited for SARS-CoV-2 vaccine development</article-title><source>Vaccines (Basel)</source><year>2020</year><volume>9</volume><issue>1</issue><elocation-id>E11</elocation-id><pub-id pub-id-type="pmid">33375677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9010011</pub-id><pub-id pub-id-type="pmcid">PMC7824029</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name></person-group><article-title>Adenoviral vector-based strategies against infectious disease and cancer</article-title><source>Hum Vaccin Immunother</source><year>2016</year><volume>12</volume><issue>8</issue><fpage>2064</fpage><lpage>2074</lpage><pub-id pub-id-type="pmid">27105067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2016.1165908</pub-id><pub-id pub-id-type="pmcid">PMC4994731</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fausther-Bovendo</surname><given-names>H</given-names></name><name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name></person-group><article-title>Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?</article-title><source>Hum Vaccin Immunother</source><year>2014</year><volume>10</volume><issue>10</issue><fpage>2875</fpage><lpage>2884</lpage><pub-id pub-id-type="pmid">25483662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.29594</pub-id><pub-id pub-id-type="pmcid">PMC5443060</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>AO</given-names></name><name name-style="western"><surname>Kafai</surname><given-names>NM</given-names></name><name name-style="western"><surname>Dmitriev</surname><given-names>IP</given-names></name><name name-style="western"><surname>Fox</surname><given-names>JM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>BK</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>IB</given-names></name><etal/></person-group><article-title>A Single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2</article-title><source>Cell</source><year>2020</year><volume>183</volume><issue>1</issue><fpage>169</fpage><lpage>184.e13</lpage><pub-id pub-id-type="pmid">32931734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.08.026</pub-id><pub-id pub-id-type="pmcid">PMC7437481</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewer</surname><given-names>K</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>S</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S</given-names></name><name name-style="western"><surname>Hill</surname><given-names>AV</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name></person-group><article-title>Chimpanzee adenoviral vectors as vaccines for outbreak pathogens</article-title><source>Hum Vaccin Immunother</source><year>2017</year><volume>13</volume><issue>12</issue><fpage>3020</fpage><lpage>3032</lpage><pub-id pub-id-type="pmid">29083948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2017.1383575</pub-id><pub-id pub-id-type="pmcid">PMC5718829</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name></person-group><article-title>Development of novel vaccine vectors: chimpanzee adenoviral vectors</article-title><source>Hum Vaccin Immunother</source><year>2018</year><volume>14</volume><issue>7</issue><fpage>1679</fpage><lpage>1685</lpage><pub-id pub-id-type="pmid">29300685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2017.1419108</pub-id><pub-id pub-id-type="pmcid">PMC6067905</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>S</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>SC</given-names></name></person-group><article-title>Simian adenoviruses as vaccine vectors</article-title><source>Future Virol</source><year>2016</year><volume>11</volume><issue>9</issue><fpage>649</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">29527232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fvl-2016-0070</pub-id><pub-id pub-id-type="pmcid">PMC5842362</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colloca</surname><given-names>S</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>E</given-names></name><name name-style="western"><surname>Folgori</surname><given-names>A</given-names></name><name name-style="western"><surname>Ammendola</surname><given-names>V</given-names></name><name name-style="western"><surname>Capone</surname><given-names>S</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species</article-title><source>Sci Transl Med</source><year>2012</year><volume>4</volume><issue>115</issue><elocation-id>115ra2</elocation-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3002925</pub-id><pub-id pub-id-type="pmcid">PMC3627206</pub-id><pub-id pub-id-type="pmid">22218691</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name name-style="western"><surname>Purushotham</surname><given-names>JN</given-names></name><name name-style="western"><surname>Port</surname><given-names>JR</given-names></name><etal/></person-group><article-title>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title><source>Nature</source><year>2020</year><volume>586</volume><issue>7830</issue><fpage>578</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">32731258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2608-y</pub-id><pub-id pub-id-type="pmcid">PMC8436420</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>SA</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><year>2021</year><volume>397</volume><issue>10269</issue><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="webpage"><collab>Mint</collab><source>Efficacy of Oxford jabs at 95% if given 3 months apart</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.livemint.com/science/health/efficacy-of-oxford-jabs-at-95-if-given-3-months-apart-sii-11609181643451.html">https://www.livemint.com/science/health/efficacy-of-oxford-jabs-at-95-if-given-3-months-apart-sii-11609181643451.html</ext-link></comment></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="webpage"><collab>Medicines and Healthcare Products Regulatory Agency of UK</collab><source>Regulatory approval of COVID-19 Vaccine AstraZeneca</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca?fbclid=IwAR0YbnbQ8ahXnDMQy6GNpAB9uPBfSSS7AggJxOaanqrdh95Js2hA3SPTFm8">https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca?fbclid=IwAR0YbnbQ8ahXnDMQy6GNpAB9uPBfSSS7AggJxOaanqrdh95Js2hA3SPTFm8</ext-link></comment></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>OV</given-names></name><name name-style="western"><surname>Tukhvatulin</surname><given-names>AI</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>DV</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia</article-title><source>Lancet</source><year>2020</year><volume>396</volume><issue>10255</issue><fpage>887</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">32896291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmcid">PMC7471804</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercado</surname><given-names>NB</given-names></name><name name-style="western"><surname>Zahn</surname><given-names>R</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Loos</surname><given-names>C</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title><source>Nature</source><year>2020</year><volume>586</volume><issue>7830</issue><fpage>583</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">32731257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2607-z</pub-id><pub-id pub-id-type="pmcid">PMC7581548</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G</given-names></name><name name-style="western"><surname>Heerwegh</surname><given-names>D</given-names></name><name name-style="western"><surname>Truyers</surname><given-names>C</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Interim results of a phase 1-2a Trial of Ad26.COV2.S Covid-19 vaccine</article-title><source>N Engl J Med</source><comment>Forthcoming</comment><year>2021</year><pub-id pub-id-type="doi">10.1056/NEJMoa2034201</pub-id><pub-id pub-id-type="pmcid">PMC7821985</pub-id><pub-id pub-id-type="pmid">33440088</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="webpage"><source>Janssen publishes positive safety and efficacy data for single-dose COVID-19 vaccine</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 29, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/news/janssen-publishes-positive-safety-and-efficacy-data-for-single-dose-covid-19-vaccine?fbclid=IwAR0nmT5gGtldli6gEej-Vt8W9HfUEEU6DKP6xelHiYAVlwpa2HX6PKeMZtg">https://www.gov.uk/government/news/janssen-publishes-positive-safety-and-efficacy-data-for-single-dose-covid-19-vaccine?fbclid=IwAR0nmT5gGtldli6gEej-Vt8W9HfUEEU6DKP6xelHiYAVlwpa2HX6PKeMZtg</ext-link></comment></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>FC</given-names></name><name name-style="western"><surname>Li</surname><given-names>YH</given-names></name><name name-style="western"><surname>Guan</surname><given-names>XH</given-names></name><name name-style="western"><surname>Hou</surname><given-names>LH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10240</issue><fpage>1845</fpage><lpage>1854</lpage><pub-id pub-id-type="pmid">32450106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Porter</surname><given-names>FW</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>mRNA vaccines - a new era in vaccinology</article-title><source>Nat Rev Drug Discov</source><year>2018</year><volume>17</volume><issue>4</issue><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Seth</surname><given-names>A</given-names></name><name name-style="western"><surname>Wibowo</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>CX</given-names></name><name name-style="western"><surname>Mitter</surname><given-names>N</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nanoparticle vaccines</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><issue>3</issue><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">24295808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.11.069</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karik&#243;</surname><given-names>K</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>FA</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>J</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name><etal/></person-group><article-title>Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability</article-title><source>Mol Ther</source><year>2008</year><volume>16</volume><issue>11</issue><fpage>1833</fpage><lpage>1840</lpage><pub-id pub-id-type="pmid">18797453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2008.200</pub-id><pub-id pub-id-type="pmcid">PMC2775451</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlake</surname><given-names>T</given-names></name><name name-style="western"><surname>Thess</surname><given-names>A</given-names></name><name name-style="western"><surname>Fotin-Mleczek</surname><given-names>M</given-names></name><name name-style="western"><surname>Kallen</surname><given-names>KJ</given-names></name></person-group><article-title>Developing mRNA-vaccine technologies</article-title><source>RNA Biol</source><year>2012</year><volume>9</volume><issue>11</issue><fpage>1319</fpage><lpage>1330</lpage><pub-id pub-id-type="pmid">23064118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/rna.22269</pub-id><pub-id pub-id-type="pmcid">PMC3597572</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>BR</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Jha</surname><given-names>BK</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>RH</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name><name name-style="western"><surname>Karik&#243;</surname><given-names>K</given-names></name></person-group><article-title>Nucleoside modifications in RNA limit activation of 2&#8242;-5&#8242;-oligoadenylate synthetase and increase resistance to cleavage by RNase L</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>21</issue><fpage>9329</fpage><lpage>9338</lpage><pub-id pub-id-type="pmid">21813458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkr586</pub-id><pub-id pub-id-type="pmcid">PMC3241635</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ohto</surname><given-names>U</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name><name name-style="western"><surname>Krayukhina</surname><given-names>E</given-names></name><name name-style="western"><surname>Taoka</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA</article-title><source>Immunity</source><year>2016</year><volume>45</volume><issue>4</issue><fpage>737</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">27742543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2016.09.011</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karik&#243;</surname><given-names>K</given-names></name><name name-style="western"><surname>Buckstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Ni</surname><given-names>H</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA</article-title><source>Immunity</source><year>2005</year><volume>23</volume><issue>2</issue><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">16111635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2005.06.008</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanji</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohto</surname><given-names>U</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name><name name-style="western"><surname>Taoka</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Isobe</surname><given-names>T</given-names></name><etal/></person-group><article-title>Toll-like receptor 8 senses degradation products of single-stranded RNA</article-title><source>Nat Struct Mol Biol</source><year>2015</year><volume>22</volume><issue>2</issue><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">25599397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nsmb.2943</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>B</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name></person-group><article-title>Stability of the osmoregulated promoter-derived proP mRNA is posttranscriptionally regulated by RNase III in Escherichia coli</article-title><source>J Bacteriol</source><year>2015</year><volume>197</volume><issue>7</issue><fpage>1297</fpage><lpage>1305</lpage><pub-id pub-id-type="pmid">25645556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JB.02460-14</pub-id><pub-id pub-id-type="pmcid">PMC4352664</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knights</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Nuber</surname><given-names>N</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>CW</given-names></name><name name-style="western"><surname>de la Rosa</surname><given-names>O</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>E</given-names></name><name name-style="western"><surname>Tiercy</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><issue>3</issue><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">18663444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-008-0556-8</pub-id><pub-id pub-id-type="pmcid">PMC11030140</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flanagan</surname><given-names>KL</given-names></name><name name-style="western"><surname>Best</surname><given-names>E</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>NW</given-names></name><name name-style="western"><surname>Giles</surname><given-names>M</given-names></name><name name-style="western"><surname>Koirala</surname><given-names>A</given-names></name><name name-style="western"><surname>Macartney</surname><given-names>K</given-names></name><etal/></person-group><article-title>Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><elocation-id>579250</elocation-id><pub-id pub-id-type="pmid">33123165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.579250</pub-id><pub-id pub-id-type="pmcid">PMC7566192</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Kream</surname><given-names>RM</given-names></name><name name-style="western"><surname>Stefano</surname><given-names>GB</given-names></name></person-group><article-title>An evidence based perspective on mRNA-SARS-CoV-2 vaccine development</article-title><source>Med Sci Monit</source><year>2020</year><volume>26</volume><elocation-id>e924700</elocation-id><pub-id pub-id-type="pmid">32366816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.924700</pub-id><pub-id pub-id-type="pmcid">PMC7218962</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>27</issue><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R</given-names></name><etal/></person-group><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>N Engl J Med</source><year>2020</year><elocation-id>NEJMoa2035389</elocation-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id><pub-id pub-id-type="pmid">33378609</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kauffman</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Mir</surname><given-names>FF</given-names></name><name name-style="western"><surname>Jhunjhunwala</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaczmarek</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hurtado</surname><given-names>JE</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo</article-title><source>Biomaterials</source><year>2016</year><volume>109</volume><fpage>78</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">27680591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2016.09.006</pub-id><pub-id pub-id-type="pmcid">PMC5267554</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="webpage"><source>CureVac's mRNA-based vaccine candidate against COVID-19</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.curevac.com/en/covid-19/">https://www.curevac.com/en/covid-19/</ext-link></comment></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sardesai</surname><given-names>NY</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name></person-group><article-title>Electroporation delivery of DNA vaccines: prospects for success</article-title><source>Curr Opin Immunol</source><year>2011</year><volume>23</volume><issue>3</issue><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">21530212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2011.03.008</pub-id><pub-id pub-id-type="pmcid">PMC3109217</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tebas</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>JD</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>EL</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Christensen-Quick</surname><given-names>A</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial</article-title><source>EClinicalMedicine</source><year>2020</year><volume>31</volume><elocation-id>100689</elocation-id><pub-id pub-id-type="pmid">33392485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2020.100689</pub-id><pub-id pub-id-type="pmcid">PMC7759123</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect Dis</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2</article-title><source>Cell</source><year>2020</year><volume>182</volume><issue>3</issue><fpage>713</fpage><lpage>721.e9</lpage><pub-id pub-id-type="pmid">32778225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.06.008</pub-id><pub-id pub-id-type="pmcid">PMC7275151</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeyanathan</surname><given-names>M</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>S</given-names></name><name name-style="western"><surname>Smaill</surname><given-names>F</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lichty</surname><given-names>BD</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z</given-names></name></person-group><article-title>Immunological considerations for COVID-19 vaccine strategies</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><issue>10</issue><fpage>615</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">32887954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-00434-6</pub-id><pub-id pub-id-type="pmcid">PMC7472682</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>JP</given-names></name><name name-style="western"><surname>Klasse</surname><given-names>PJ</given-names></name></person-group><article-title>COVID-19 vaccines: &#8220;warp speed&#8221; needs mind melds, not warped minds</article-title><source>J Virol</source><year>2020</year><volume>94</volume><issue>17</issue><fpage>e01083</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">32591466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01083-20</pub-id><pub-id pub-id-type="pmcid">PMC7431783</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase 1&#8211;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>24</issue><fpage>2320</fpage><lpage>2332</lpage><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="webpage"><source>Novavax publishes positive efficacy data for its COVID-19 vaccine</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 30, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/news/novavax-publishes-positive-efficacy-data-for-its-covid-19-vaccine?fbclid=IwAR3B5FI8NYLvHn3R-IxCC049TLdwHcOsJxZxA16qHM7n2NIw7P37tb47Edo">https://www.gov.uk/government/news/novavax-publishes-positive-efficacy-data-for-its-covid-19-vaccine?fbclid=IwAR3B5FI8NYLvHn3R-IxCC049TLdwHcOsJxZxA16qHM7n2NIw7P37tb47Edo</ext-link></comment></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="webpage"><source>What to expect after getting a COVID-19 vaccine</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html</ext-link></comment></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="webpage"><source>COVID-19 vaccines and allergic reactions</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergic-reaction.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergic-reaction.html</ext-link></comment></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimabukuro</surname><given-names>T</given-names></name><name name-style="western"><surname>Nair</surname><given-names>N</given-names></name></person-group><article-title>Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine</article-title><source>JAMA</source><comment>Forthcoming</comment><year>2021</year><pub-id pub-id-type="doi">10.1001/jama.2021.0600</pub-id><pub-id pub-id-type="pmcid">PMC8892260</pub-id><pub-id pub-id-type="pmid">33475702</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="webpage"><source>What are the various ingredients in the COVID-19 vaccines?</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.goodrx.com/blog/ingredients-covid-19-vaccine/">https://www.goodrx.com/blog/ingredients-covid-19-vaccine/</ext-link></comment></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="webpage"><source>Emergency use authorization (EUA) of The Pfizer-Biontech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 16 years of age and older</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/144414/download">https://www.fda.gov/media/144414/download</ext-link></comment></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="webpage"><source>Emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) In Individuals 18 years of age and older</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/144638/download">https://www.fda.gov/media/144638/download</ext-link></comment></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabanillas</surname><given-names>B</given-names></name><name name-style="western"><surname>Akdis</surname><given-names>C</given-names></name><name name-style="western"><surname>Novak</surname><given-names>N</given-names></name></person-group><article-title>Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol?</article-title><source>Allergy</source><comment>Forthcoming</comment><year>2020</year><pub-id pub-id-type="doi">10.1111/all.14711</pub-id><pub-id pub-id-type="pmid">33320974</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganson</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Povsic</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Sullenger</surname><given-names>BA</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>JH</given-names></name><name name-style="western"><surname>Zelenkofske</surname><given-names>SL</given-names></name><name name-style="western"><surname>Sailstad</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer</article-title><source>J Allergy Clin Immunol</source><year>2016</year><volume>137</volume><issue>5</issue><fpage>1610</fpage><lpage>1613.e7</lpage><pub-id pub-id-type="pmid">26688515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2015.10.034</pub-id><pub-id pub-id-type="pmcid">PMC5819876</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castells</surname><given-names>MC</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>EJ</given-names></name></person-group><article-title>Maintaining safety with SARS-CoV-2 vaccines</article-title><source>N Engl J Med</source><comment>Forthcoming</comment><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMra2035343</pub-id><pub-id pub-id-type="pmcid">PMC7787218</pub-id><pub-id pub-id-type="pmid">33378605</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="webpage"><source>Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html">https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html</ext-link></comment></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallapaty</surname><given-names>S</given-names></name><name name-style="western"><surname>Ledford</surname><given-names>H</given-names></name></person-group><article-title>COVID-vaccine results are on the way - and scientists' concerns are growing</article-title><source>Nature</source><year>2020</year><volume>586</volume><issue>7827</issue><fpage>16</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">32978611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-020-02706-6</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="webpage"><source>Vaccines and related biological products advisory committee meeting December 10, 2020</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 30, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/144245/download">https://www.fda.gov/media/144245/download</ext-link></comment></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="webpage"><source>Vaccines and related biological products advisory committee December 17, 2020</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 30, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/144585/download">https://www.fda.gov/media/144585/download</ext-link></comment></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><collab>Centers for Disease Control and Prevention (CDC)</collab><article-title>Syncope after vaccination--United States, January 2005-July 2007</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2008</year><volume>57</volume><issue>17</issue><fpage>457</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">18451756</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torjesen</surname><given-names>I</given-names></name></person-group><article-title>Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination</article-title><source>BMJ</source><year>2021</year><volume>372</volume><issue>149</issue><fpage>n149</fpage><pub-id pub-id-type="pmid">33451975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n149</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Molecular mechanism for antibody-dependent enhancement of coronavirus entry</article-title><source>J Virol</source><year>2020</year><volume>94</volume><issue>5</issue><fpage>e02015</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">31826992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02015-19</pub-id><pub-id pub-id-type="pmcid">PMC7022351</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitehead</surname><given-names>SS</given-names></name><name name-style="western"><surname>Blaney</surname><given-names>JE</given-names></name><name name-style="western"><surname>Durbin</surname><given-names>AP</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>BR</given-names></name></person-group><article-title>Prospects for a dengue virus vaccine</article-title><source>Nat Rev Microbiol</source><year>2007</year><volume>5</volume><issue>7</issue><fpage>518</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">17558424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro1690</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>WS</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>DeKosky</surname><given-names>BJ</given-names></name></person-group><article-title>Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies</article-title><source>Nat Microbiol</source><year>2020</year><volume>5</volume><issue>10</issue><fpage>1185</fpage><lpage>1191</lpage><pub-id pub-id-type="pmid">32908214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-00789-5</pub-id><pub-id pub-id-type="pmcid">PMC12103240</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>The potential danger of suboptimal antibody responses in COVID-19</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><issue>6</issue><fpage>339</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">32317716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0321-6</pub-id><pub-id pub-id-type="pmcid">PMC7187142</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotez</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Corry</surname><given-names>DB</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>ME</given-names></name></person-group><article-title>COVID-19 vaccine design: the Janus face of immune enhancement</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><issue>6</issue><fpage>347</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">32346094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0323-4</pub-id><pub-id pub-id-type="pmcid">PMC7187801</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanche</surname><given-names>S</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YT</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Romero-Severson</surname><given-names>E</given-names></name><name name-style="western"><surname>Hengartner</surname><given-names>N</given-names></name><name name-style="western"><surname>Ke</surname><given-names>R</given-names></name></person-group><article-title>High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2</article-title><source>Emerg Infect Dis</source><year>2020</year><volume>26</volume><issue>7</issue><fpage>1470</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">32255761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2607.200282</pub-id><pub-id pub-id-type="pmcid">PMC7323562</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name name-style="western"><surname>Norddahl</surname><given-names>GL</given-names></name><name name-style="western"><surname>Melsted</surname><given-names>P</given-names></name><name name-style="western"><surname>Gunnarsdottir</surname><given-names>K</given-names></name><name name-style="western"><surname>Holm</surname><given-names>H</given-names></name><name name-style="western"><surname>Eythorsson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Humoral immune response to SARS-CoV-2 in Iceland</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>18</issue><fpage>1724</fpage><lpage>1734</lpage><pub-id pub-id-type="pmid">32871063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2026116</pub-id><pub-id pub-id-type="pmcid">PMC7494247</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Widge</surname><given-names>AT</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>PC</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M</given-names></name><etal/></person-group><article-title>Durability of responses after SARS-CoV-2 mRNA-1273 vaccination</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><issue>1</issue><fpage>80</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">33270381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2032195</pub-id><pub-id pub-id-type="pmcid">PMC7727324</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L'Huillier</surname><given-names>AG</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>B</given-names></name><name name-style="western"><surname>Andrey</surname><given-names>DO</given-names></name><name name-style="western"><surname>Arm-Vernez</surname><given-names>I</given-names></name><name name-style="western"><surname>Baggio</surname><given-names>S</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antibody persistence in the first six months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study</article-title><source>Clin Microbiol Infect</source><comment>Forthcoming</comment><year>2021</year><pub-id pub-id-type="doi">10.1016/j.cmi.2021.01.005</pub-id><pub-id pub-id-type="pmcid">PMC7816882</pub-id><pub-id pub-id-type="pmid">33482352</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>J</given-names></name><name name-style="western"><surname>Kato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>KM</given-names></name><name name-style="western"><surname>Yu</surname><given-names>ED</given-names></name><name name-style="western"><surname>Faliti</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection</article-title><source>Science</source><comment>Forthcoming</comment><year>2021</year><pub-id pub-id-type="doi">10.1126/science.abf4063</pub-id><pub-id pub-id-type="pmcid">PMC7919858</pub-id><pub-id pub-id-type="pmid">33408181</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Chand</surname><given-names>M</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>S</given-names></name><name name-style="western"><surname>Dabrera</surname><given-names>G</given-names></name><name name-style="western"><surname>Achison</surname><given-names>C</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>W</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>N</given-names></name><etal/></person-group><source>Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01 (PDF) (Report)</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201">https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201</ext-link></comment></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="webpage"><source>Public Health England. Technical briefing document on novel SARS-COV-2 variant</source><date-in-citation content-type="updated">Updated 2020</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201">https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201</ext-link></comment></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wise</surname><given-names>J</given-names></name></person-group><article-title>Covid-19: new coronavirus variant is identified in UK</article-title><source>BMJ</source><year>2020</year><volume>371</volume><fpage>m4857</fpage><pub-id pub-id-type="pmid">33328153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.m4857</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korber</surname><given-names>B</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>WM</given-names></name><name name-style="western"><surname>Gnanakaran</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H</given-names></name><name name-style="western"><surname>Theiler</surname><given-names>J</given-names></name><name name-style="western"><surname>Abfalterer</surname><given-names>W</given-names></name><etal/></person-group><article-title>Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus</article-title><source>Cell</source><year>2020</year><volume>182</volume><issue>4</issue><fpage>812</fpage><lpage>827.e19</lpage><pub-id pub-id-type="pmid">32697968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.06.043</pub-id><pub-id pub-id-type="pmcid">PMC7332439</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E</given-names></name></person-group><article-title>Could new COVID variants undermine vaccines? Labs scramble to find out</article-title><source>Nature</source><year>2021</year><volume>589</volume><issue>7841</issue><fpage>177</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">33432212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-021-00031-0</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Pater</surname><given-names>AA</given-names></name><name name-style="western"><surname>Bosmeny</surname><given-names>MS</given-names></name><name name-style="western"><surname>Barkau</surname><given-names>CL</given-names></name><name name-style="western"><surname>Ovington</surname><given-names>KN</given-names></name><name name-style="western"><surname>Chilamkurthy</surname><given-names>R</given-names></name><name name-style="western"><surname>Parasrampuria</surname><given-names>M</given-names></name><etal/></person-group><source>Emergence and evolution of a prevalent new SARS-CoV-2 variant in the United States</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.01.11.426287v1">https://www.biorxiv.org/content/10.1101/2021.01.11.426287v1</ext-link></comment></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weisblum</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>DaSilva</surname><given-names>J</given-names></name><name name-style="western"><surname>Poston</surname><given-names>D</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title><source>eLife</source><year>2020</year><volume>9</volume><elocation-id>e61312</elocation-id><pub-id pub-id-type="pmid">33112236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.61312</pub-id><pub-id pub-id-type="pmcid">PMC7723407</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Muik</surname><given-names>A</given-names></name><name name-style="western"><surname>Wallisch</surname><given-names>AK</given-names></name><name name-style="western"><surname>Sanger</surname><given-names>B</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>KA</given-names></name><name name-style="western"><surname>Muhl</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><source>Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.01.18.426984v1">https://www.biorxiv.org/content/10.1101/2021.01.18.426984v1</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abg6105</pub-id><pub-id pub-id-type="pmcid">PMC7971771</pub-id><pub-id pub-id-type="pmid">33514629</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dearlove</surname><given-names>B</given-names></name><name name-style="western"><surname>Lewitus</surname><given-names>E</given-names></name><name name-style="western"><surname>Bai</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>DB</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><etal/></person-group><article-title>A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><issue>38</issue><fpage>23652</fpage><lpage>23662</lpage><pub-id pub-id-type="pmid">32868447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2008281117</pub-id><pub-id pub-id-type="pmcid">PMC7519301</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Collier</surname><given-names>DA</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>IA</given-names></name><name name-style="western"><surname>Datir</surname><given-names>R</given-names></name><name name-style="western"><surname>Temperton</surname><given-names>N</given-names></name><name name-style="western"><surname>Elmer</surname><given-names>A</given-names></name><etal/></person-group><source>Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2021.01.19.21249840v1">https://www.medrxiv.org/content/10.1101/2021.01.19.21249840v1</ext-link></comment></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kistler</surname><given-names>KE</given-names></name><name name-style="western"><surname>Bedford</surname><given-names>T</given-names></name></person-group><article-title>Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229E</article-title><source>eLife</source><year>2021</year><volume>10</volume><elocation-id>e64509</elocation-id><pub-id pub-id-type="pmid">33463525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.64509</pub-id><pub-id pub-id-type="pmcid">PMC7861616</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Wibmer</surname><given-names>CK</given-names></name><name name-style="western"><surname>Ayres</surname><given-names>F</given-names></name><name name-style="western"><surname>Hermanus</surname><given-names>T</given-names></name><name name-style="western"><surname>Madzivhandila</surname><given-names>M</given-names></name><name name-style="western"><surname>Kgagudi</surname><given-names>P</given-names></name><name name-style="western"><surname>Lambson</surname><given-names>BE</given-names></name><etal/></person-group><source>SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1">https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1</ext-link></comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01285-x</pub-id><pub-id pub-id-type="pmid">33654292</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E</given-names></name></person-group><article-title>Fast-spreading COVID variant can elude immune responses</article-title><source>Nature</source><year>2021</year><volume>589</volume><issue>7843</issue><fpage>500</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">33479534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-021-00121-z</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><name name-style="western"><surname>Werner</surname><given-names>AP</given-names></name><name name-style="western"><surname>Moliva</surname><given-names>JI</given-names></name><name name-style="western"><surname>Koch</surname><given-names>M</given-names></name><name name-style="western"><surname>Choi</surname><given-names>A</given-names></name><name name-style="western"><surname>Stewart-Jones</surname><given-names>GB</given-names></name><etal/></person-group><source>mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1">https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1</ext-link></comment></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Potential antivirals and antiviral strategies against SARS coronavirus infections</article-title><source>Expert Rev Anti Infect Ther</source><year>2006</year><volume>4</volume><issue>2</issue><fpage>291</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">16597209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14787210.4.2.291</pub-id><pub-id pub-id-type="pmcid">PMC7105749</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Totura</surname><given-names>AL</given-names></name><name name-style="western"><surname>Bavari</surname><given-names>S</given-names></name></person-group><article-title>Broad-spectrum coronavirus antiviral drug discovery</article-title><source>Expert Opin Drug Discov</source><year>2019</year><volume>14</volume><issue>4</issue><fpage>397</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">30849247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17460441.2019.1581171</pub-id><pub-id pub-id-type="pmcid">PMC7103675</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agoni</surname><given-names>C</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>ME</given-names></name></person-group><article-title>The binding of remdesivir to SARS-CoV-2 RNA-dependent RNA polymerase may pave the way towards the design of potential drugs for COVID-19 treatment</article-title><source>Curr Pharm Biotechnol</source><comment>Forthcoming</comment><year>2020</year><pub-id pub-id-type="doi">10.2174/1389201021666201027154833</pub-id><pub-id pub-id-type="pmid">33109039</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name></person-group><article-title>Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China</article-title><source>Virus Res</source><year>2020</year><volume>286</volume><elocation-id>198057</elocation-id><pub-id pub-id-type="pmid">32531236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virusres.2020.198057</pub-id><pub-id pub-id-type="pmcid">PMC7282797</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chik</surname><given-names>KK</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>JO</given-names></name><name name-style="western"><surname>Liang</surname><given-names>R</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Broad-spectrum host-based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic coronavirus disease 2019 (COVID-19)</article-title><source>Viruses</source><year>2020</year><volume>12</volume><issue>6</issue><fpage>628</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v12060628</pub-id><pub-id pub-id-type="pmcid">PMC7354423</pub-id><pub-id pub-id-type="pmid">32532085</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Boras</surname><given-names>B</given-names></name><name name-style="western"><surname>Jones</surname><given-names>RM</given-names></name><name name-style="western"><surname>Anson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Arenson</surname><given-names>D</given-names></name><name name-style="western"><surname>Aschenbrenner</surname><given-names>L</given-names></name><name name-style="western"><surname>Bakowski</surname><given-names>MA</given-names></name><etal/></person-group><source>Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19</source><date-in-citation content-type="updated">Updated 2021</date-in-citation><date-in-citation content-type="access-date">Accessed January 31, 2021</date-in-citation><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.09.12.293498v2">https://www.biorxiv.org/content/10.1101/2020.09.12.293498v2</ext-link></comment></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>WF</given-names></name><name name-style="western"><surname>Stephen</surname><given-names>P</given-names></name><name name-style="western"><surname>Th&#233;riault</surname><given-names>JF</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Lin</surname><given-names>SX</given-names></name></person-group><article-title>Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks</article-title><source>J Phys Chem Lett</source><year>2020</year><volume>11</volume><issue>11</issue><fpage>4430</fpage><lpage>4435</lpage><pub-id pub-id-type="pmid">32392072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jpclett.0c00571</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slanina</surname><given-names>H</given-names></name><name name-style="western"><surname>Madhugiri</surname><given-names>R</given-names></name><name name-style="western"><surname>Bylapudi</surname><given-names>G</given-names></name><name name-style="western"><surname>Schulthei&#223;</surname><given-names>K</given-names></name><name name-style="western"><surname>Karl</surname><given-names>N</given-names></name><name name-style="western"><surname>Gulyaeva</surname><given-names>A</given-names></name><etal/></person-group><article-title>Coronavirus replication-transcription complex: vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit</article-title><source>Proc Natl Acad Sci U S A</source><year>2021</year><volume>118</volume><issue>6</issue><elocation-id>e2022310118</elocation-id><pub-id pub-id-type="pmid">33472860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2022310118</pub-id><pub-id pub-id-type="pmcid">PMC8017715</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>